SCHEMBL2118244

SCHEMBL2118244

Cc1ccc(-c2cccnc2)cc1NS(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.51
ABCC1 P33527 1/20 0.51
POLB P06746 1/20 0.49
CKS1B P61024 1/20 0.47
SKP2 Q13309 1/20 0.47
ABL1 P00519 1/20 0.47
BCR P11274 1/20 0.47
HTR6 P50406 1/20 0.47
NAMPT P43490 3/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
PIK3CG P48736 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
PIK3CD O00329 2/20 0.45
CYP11B1 P15538 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120534 0.88 ABCB1 (0.51) ABCB1ABCC1POLBCKS1BSKP2
SCHEMBL2118531 0.88 NAMPT (0.55) ABCB1ABCC1POLBCKS1BSKP2
SCHEMBL2118451 0.85 ALDH1A1 (0.48) POLBHTR6SMN1; SMN2MEN1KMT2A
SCHEMBL2117690 0.85 ABCB1 (0.61) ABCB1ABCC1POLBCKS1BSKP2
SCHEMBL2119919 0.83 MCL1 (0.57) POLBHTR6CA1CA2CA9
SCHEMBL2118236 0.81 CYP2C9 (0.54) POLBHTR6CA12CA1CA2
SCHEMBL2120602 0.80 HSD11B1 (0.45) PIK3CGSMN1; SMN2TDP1PIK3CDCYP11B1
SCHEMBL22230488 0.80 PIK3CG (0.56) PIK3CGPIK3CDPIK3CAPIK3CBMTOR
SCHEMBL2119235 0.79 ABCB1 (0.71) ABCB1ABCC1KMT2ACYP11B1CYP11B2
SCHEMBL2121436 0.79 POLB (0.51) POLBPIK3CGSMN1; SMN2KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 ABCB1 2175/4885ABCC1 1204/4885POLB 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.